Global Lung Cancer Diagnostic Test Market is estimated to be US$ 4.07 billion by 2030 with a CAGR of 7.50% during the forecast period - By PMI

Covina, April 19, 2022 (GLOBE NEWSWIRE) -- Lung cancer starts in the lungs and can spread to the lymph nodes or other body organs, including the brain. Cancer that has progressed to other organs can potentially spread to the lungs. Metastases are the spread of cancer cells from one organ to another. Small cell and non-small cell lung tumors are the two most common kinds of lung cancer. These kinds of lung cancer grow and respond to treatment in different ways. Non-small cell lung cancer is more prevalent than small cell lung cancer, according to the American Cancer Society. Lung cancer symptoms range from person to person. Symptoms of the lungs affect some persons.

Region Analysis:

North America dominates the lung cancer diagnostics market, due to rising incidence of lung cancer and the ageing population in the particular region. North America is regarded as the largest regional market with the highest market share due to increased market invasion rates of technologically advanced products, rising patient awareness, and rising smoking prevalence levels in the region are all factors contributing to the region's greatest market share. Due to increased use of lung cancer diagnostics due to rising tobacco smoking in the region, Asia-Pacific (APAC) is predicted to have considerable growth over the projection period. 

Request Free Sample Copy: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4863

Key Development:

• AnPac Bio-Medical Science Co., Ltd, a biotechnology company focused on early cancer screening and detection with operations in China and the United States, announced on January 25, 2021, that China's medical product regulatory authority, the National Medical Products Administration, had approved AnPac Bio to begin registration testing of its Class III lung cancer auxiliary diagnosis medical device at a designated medical device testing laboratory, which is a sign of progress.
• Amgen established significant partnerships with renowned diagnostic companies Guardant Health, Inc. and QIAGEN N.V. in January 2020 to develop blood and tissue-based companion diagnostics (CDx) for the investigational cancer therapy AMG 510, respectively. AMG 510 is the first KRASG12C inhibitor to make it to the clinic, where it will be studied in the treatment of a variety of tumour types. In human cancer, KRAS G12C is one of the most frequently mutated oncogenes. The CDx tests for non-small cell lung cancer will be the focus of the agreements with both firms at first (NSCLC).

To know the upcoming trends and insights prevalent in this market, click the link below:

Links- https://www.prophecymarketinsights.com/market_insight/Global-Lung-Cancer-Diagnostic-Test-Market-4863

Segmentation:

Global Lung Cancer Diagnostic Test Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 4.07 billion by 2030 and is anticipated to register a CAGR of 7.50%. The Global Lung Cancer Diagnostic Test Market is segmented by Test Type, Cancer Type, End-Use Industry and Region.

• By Test Type, the Global Lung Cancer Diagnostic Test Market is segmented into Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others.
• By Cancer Type, the Global Lung Cancer Diagnostic Test Market is classified into Non-small cell lung cancer and Small Cell Lung Cancer.
• By End-Use Industry, the Global Lung Cancer Diagnostic Test Market is classified into Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others.
• By region, the Global Lung Cancer Diagnostic Test Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Analysis:                                                                                                 

The key players operating in the Global Lung Cancer Diagnostic Test Market includes Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.

Scope of the Report: 

1. Global Lung Cancer Diagnostic Test Market , By Test Type, 2020 – 2030, (US$ Mn)
   • Overview      
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Biomarkers Test
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Imaging Test
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Biopsy
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
2. Global Lung Cancer Diagnostic Test Market , By Application, 2020 – 2030, (US$ Mn)
   • Overview 
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Non-Small Cell Lung Cancer
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Small Cell Lung Cancer
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
3. Global Lung Cancer Diagnostic Test Market , By End-Use Industry, 2020 – 2030, (US$ Mn)
   • Overview    
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
     • Y-o-Y Growth Analysis (%), 2020 – 2030
     • Segment Trends
   • Hospital Associated Labs
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Independent Diagnostic Laboratories
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Diagnostic Imaging Centers
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Cancer Research Centers
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
   • Others
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

For Customization: https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/4863

About Prophecy Market Insights 

Prophecy Market Insights is market research, analysis, marketing/business strategy and customized solutions that provide strategic and tactical support to clients to make informed business decisions and identify and achieve high value opportunities in target business areas. We also help our clients solve business challenges and provide the best solutions to overcome them and transform their business.
Following are some of the key points answered in this market report:

• Describe a product portfolio review, including product development, planning, and positioning
• Describes the details of key operational strategies, focusing on R&D strategy, company structure, localization strategy, manufacturing capabilities, and financial performance of various companies.
• Detailed analysis of market earnings over the forecast period.
• Examine various market prospects using Porter's Five Forces Analysis, PEST and SWOT analysis.
• Examine the segments that are expected to dominate the market.
• Study the regional analysis that is expected to record the highest growth during the forecast period.

Browse Related Reports: 

1. Global Cancer Diagnostics Market, By Method (Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Fluorescent Assay (ELFA), Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunohistochemistry, Microarray, Imaging, Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), Positron Emission Tomography (PET), Ultrasound, Mammography, Biopsy, and Others), By Disease Indication (Breast cancer, Colorectal cancer, Cervical cancer, Lung cancer, Prostate cancer, Skin cancer, Blood cancer, Kidney cancer, Liver cancer, Pancreatic cancer, Ovarian cancer, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) - Trends, Analysis, and Forecast till 2030
2. Global Next Generation Cancer Diagnostics Market, By Technology (RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others), By Cancer Type (Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others), By Application (CTC Analysis, Biomarker, Proteomic Analysis and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030